drugset / Trial / NCT01679561

Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial

NCT01679561

NaSingle-groupOpen-labelTreatment

Summary

Both organ-specific and systemic autoimmunity are associated with an increased prevalence of recurrent miscarriage and reproductive failure, rendering the role of the maternal immunological system in fertility a key concept. It is believed by some that central to this theme is the maternal cytokine profile, with particularly T-helper (Th) cells. Immune modulating therapies have therefore been mooted as potential therapeutic strategies. Recent reports of high pregnancy rates achievable in women with RIF have added fuel to the debate regarding the effectiveness of intralipids in modulating the immune system.

Timeline

Start
2012-02
Primary completion
2012-08
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Intralipid Other / unclassified 2 ml Intravenous
Subject Intralipid Other / unclassified 4 ml Intravenous